Gram-Negative Infections | TreatmentTrends | EU | 2014
Serious Gram-negative (GN) pathogens are clinically-important pathogens in both the hospital and outpatient settings. GN pathogens are often acquired in healthcare facilities, and therefore have a high incidence of drug resistance to even the most powerful of antibiotics (e.g. third-generation cephalosporins, fluoroquinolones, and carbapenems). The increase in emergence of drug resistance, including resistance to multiple classes of antibiotics and the dearth of newly approved agents in the last ten years has resulted in a high need for new therapies for multi-drug-resistant (MDR) GN pathogens.
This report provides insight into the management of patients with GN infections in the hospital setting and analyzes the hospital antibiotic prescribing practices for the treatment of key infections due to emerging and clinically-important Gram-negative pathogens in Europe. The study provides longitudinal information on market dynamics, including insight into practice patterns, attitudes and perceptions, unmet needs, and projected use of antibiotics in the hospital setting. These studies also explore the perceived advantages and disadvantages of currently available therapies and therapies in development.
